- Home
- BIIB vs FLEX Comparison
BIIB vs FLEX Comparison
Compare BIIB & FLEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- FLEX
- Stock Information
- Founded
- BIIB 1978
- FLEX 1990
- Country
- BIIB United States
- FLEX United States
- Employees
- BIIB N/A
- FLEX N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- FLEX Electrical Products
- Sector
- BIIB Health Care
- FLEX Technology
- Exchange
- BIIB Nasdaq
- FLEX Nasdaq
- Market Cap
- BIIB 18.7B
- FLEX 23.3B
- IPO Year
- BIIB 1991
- FLEX 1994
- Fundamental
- Price
- BIIB $158.35
- FLEX $62.08
- Analyst Decision
- BIIB Buy
- FLEX Strong Buy
- Analyst Count
- BIIB 24
- FLEX 8
- Target Price
- BIIB $174.62
- FLEX $63.75
- AVG Volume (30 Days)
- BIIB 1.6M
- FLEX 4.2M
- Earning Date
- BIIB 10-30-2025
- FLEX 10-29-2025
- Dividend Yield
- BIIB N/A
- FLEX N/A
- EPS Growth
- BIIB N/A
- FLEX 1.03
- EPS
- BIIB 10.97
- FLEX 2.28
- Revenue
- BIIB $10,065,900,000.00
- FLEX $26,333,000,000.00
- Revenue This Year
- BIIB $2.97
- FLEX $6.84
- Revenue Next Year
- BIIB N/A
- FLEX $5.79
- P/E Ratio
- BIIB $14.24
- FLEX $27.92
- Revenue Growth
- BIIB 4.77
- FLEX 3.47
- 52 Week Low
- BIIB $110.04
- FLEX $25.11
- 52 Week High
- BIIB $175.86
- FLEX $67.00
- Technical
- Relative Strength Index (RSI)
- BIIB 64.86
- FLEX 50.10
- Support Level
- BIIB $151.83
- FLEX $60.79
- Resistance Level
- BIIB $157.79
- FLEX $64.98
- Average True Range (ATR)
- BIIB 4.84
- FLEX 2.79
- MACD
- BIIB 0.61
- FLEX -0.40
- Stochastic Oscillator
- BIIB 96.46
- FLEX 38.51
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About FLEX Flex Ltd.
Flex Ltd is a contract manufacturing company providing comprehensive electronics design, manufacturing, and product management services to electronics and technology companies. The company's operating segments include Flex Agility Solutions (FAS) and Flex Reliability Solutions (FRS). Flex Agility Solutions segment includes markets such as Communications, Enterprise and Cloud; Lifestyle; and Consumer Devices. Flex Reliability Solutions segment includes markets such as Automotive, Health Solutions, and Industrial.